Analyst Price Targets — EYPT
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 19, 2026 12:17 pm | — | Mizuho Securities | $36.00 | $14.36 | TheFly | EyePoint price target raised to $36 from $33 at Mizuho |
| February 5, 2026 1:54 pm | Lisa Walter | RBC Capital | $39.00 | $13.22 | StreetInsider | RBC Capital on EyePoint Inc. (EYPT): 'We See Recent Weakness as Buying Opportunity' |
| October 29, 2025 12:50 pm | Graig Suvannavejh | Mizuho Securities | $33.00 | $12.25 | TheFly | EyePoint price target raised to $33 from $28 at Mizuho |
| October 20, 2025 10:55 am | Graig Suvannavejh | Mizuho Securities | $28.00 | $11.63 | StreetInsider | Mizuho Reiterates Outperform Rating on EyePoint Pharmaceuticals, Inc. (EYPT) |
| November 11, 2024 12:23 pm | Yi Chen | H.C. Wainwright | $22.00 | $11.59 | StreetInsider | EyePoint Pharmaceuticals, Inc. (EYPT) PT Lowered to $22 at H.C. Wainwright |
| May 13, 2024 7:17 am | Yi Chen | H.C. Wainwright | $30.00 | $12.17 | StreetInsider | EyePoint Pharmaceuticals, Inc. (EYPT) PT Lowered to $30 at H.C. Wainwright |
| May 7, 2024 6:34 am | Graig Suvannavejh | Mizuho Securities | $30.00 | $11.20 | StreetInsider | EyePoint Pharmaceuticals, Inc. (EYPT) PT Lowered to $30 at Mizuho |
| August 4, 2022 6:36 am | — | H.C. Wainwright | $25.00 | $10.22 | Benzinga | HC Wainwright & Co. Maintains Buy on EyePoint Pharmaceuticals, Raises Price Target to $25 |
Latest News for EYPT
WATERTOWN, Mass., April 16, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company's 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule…
Aberdeen Group plc boosted its position in Eyepoint Pharmaceuticals, Inc. (NASDAQ: EYPT) by 101.6% in the undefined quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,605,984 shares of the company's stock after purchasing an additional 809,182 shares during the quarter. Aberdeen Group plc owned
Executives from Eyepoint Pharmaceuticals (NASDAQ: EYPT) told investors at RBC Capital Markets' Ophthalmology Conference that the company's lead program, DURAVYU (vorolanib), is advancing through four Phase 3 studies in retinal disease, with the first top-line readout expected around August. Lead program and Phase 3 timeline Chief Executive Officer Jay Duker said DURAVYU is a small-molecule tyrosine
WATERTOWN, Mass, March 16, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company's 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule…
Parkman bought 1,088,033 shares of EyePoint in the fourth quarter, marking a new stake for the fund. The quarter-end value of the EyePoint position increased by $19.88 million as a result.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for EYPT.
U.S. House Trading
No House trades found for EYPT.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.